Lessons from drug revenue life cycles: distributions across modalities and therapeutic areas

Nature Biotechnology
(2026) Cite this article

An analysis of FDA-approved drugs reveals uneven timing and concentration of revenue life cycles across modalities and therapeutic areas, offering evidence to guide innovation strategy and policy design in a post-Inflation Reduction Act world.

This is a preview of subscription content, access via your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

Receive 12 print issues and online access

Prices may be subject to local taxes which are calculated during checkout

Schuhmacher, A., Hinder, M., Boger, N., Hartl, D. & Gassmann, O. Nat. Rev. Drug Discov. 22, 177–178 (2023).

Article 
CAS 
PubMed 

Google Scholar 

Grabowski, H. G. & Vernon, J. Pharmacoeconomics 18, 21–32 (2000).

Article 
PubMed 

Google Scholar 

Berndt, E. R., Nass, D., Kleinrock, M. & Aitken, M. Health Aff. (Millwood) 34, 245–252 (2015).

Article 
PubMed 

Google Scholar 

Wouters, O. J., Kesselheim, A. S., Kuha, J. & Luyten, J. Value Health 27, 1373–1381 (2024).

Article 
PubMed 

Google Scholar 

Source: Read the original article on www.nature.com